An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs
- 22 March 2023
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 252, 115300
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Targeting Poly (ADP-Ribose) Polymerase Partially Contributes to Bufalin-Induced Cell Death in Multiple Myeloma CellsPLOS ONE, 2013
- Impact of Lipophilic Efficiency on Compound QualityJournal of Medicinal Chemistry, 2012
- Matched Molecular Pairs as a Medicinal Chemistry ToolJournal of Medicinal Chemistry, 2011
- Molecular Modeling Studies on Benzimidazole Carboxamide Derivatives as PARP‐1 Inhibitors Using 3D‐QSAR and DockingChemical Biology & Drug Design, 2011
- Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics SimulationsJournal of Chemical Information and Modeling, 2010
- Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to ClinicJournal of Medicinal Chemistry, 2010
- Improving Compound Quality through in vitro and in silico Physicochemical ProfilingChemistry & Biodiversity, 2009
- Physiochemical drug properties associated with in vivo toxicological outcomesBioorganic & Medicinal Chemistry Letters, 2008
- Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical ApplicationsProgress in Biophysics and Molecular Biology, 2005
- Virtual screening of chemical librariesNature, 2004